OptimizeRx Reports Third Quarter 2017 Results; Net Revenue Up 74% to Record $3.1 Million
Q3 2017 Highlights
- Net revenue increased 74% to a record
$3.1 million, driven by growth in financial and brand messaging by new and returning clients.
- Financial messages, such as eCoupons, and brand messaging were distributed for more than 100 pharmaceutical brands during the quarter.
- Operating expense as a percentage of revenue improved to 65.4% versus 73.5% in the year-ago quarter.
- Appointed prominent health IT veteran,
Miriam Paramore, as president to drive scale as OptimizeRxoffers medication savings at point-of-care.
- Launched automated financial messaging within iSalus Healthcare’s EHR, alerting health care providers (HCPs) to potential prescription savings and support information for their patients.
- Added several business development and operations team members to accelerate revenue growth, brand expansion and new product sales.
Q3 2017 Financial Summary
Net revenue in the third quarter of 2017 increased 74% to
Operating expenses in the third quarter of 2017 were
Net loss for the third quarter of 2017 was
Cash and cash equivalents totaled
“In Q3, our record topline was driven by the growth of our financial and brand messaging products, as well as the expansion of our EHR network through which those products are distributed to HCPs,” said
“During the quarter, we also continued to see the expansion of clients, brands, and agencies advising the industry about our cloud-based EHR channel. To support further growth and drive scale, we appointed
“These investments in our executive and sales teams have already begun to produce returns in terms of accelerated revenue growth, broader client base, and greater scale potential. In fact, our operating expenses as a percentage of revenue decreased markedly during the quarter. We see this decrease as demonstrative of the substantial leverage in our operating model, in that it supports greater market reach and revenue growth without the need to incrementally increase operating cost in a matching fashion. So, as we grow, we expect operating expense as a percentage of revenue to continue to decrease.
“Our success in acquiring, integrating and expanding into new promotional EHR/eRx platforms has also continued to strengthen. As a result, we have more master service agreements now than ever before. We recently added Aprima Medical Software, and we are actively engaged in discussions with several additional EHRs to integrate our technology into their platforms. We are also working extensively with our existing platforms to expand the reach of our financial messaging to additional health care providers, as well as increasing the utilization by existing users.
“We believe EHR adoption is here to stay, e-prescription has become well adopted, and point-of-care access is proving highly valuable to pharma. All of this is conducive to the growth of our unique marketing channel between pharma companies and HCPs. We also believe we have only just begun to scratch the surface of our market potential. So, with the growth of pharma brands, channel partners and HCPs on our EHR network, we expect the distribution of our financial messaging will continue to increase, and our brand messaging will continue to support top-line growth.
“For the remainder of the year and beyond, we will remain focused on engaging more brands, and developing more solutions and more reach. Given the greater visibility into our expanding client base, we believe we are well on track for another record quarter ahead.”
Toll-free dial-in number: 1-800-406-5345
International dial-in number: 1-719-457-2644
Conference ID: 4446715
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.
A replay of the call will be available after
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 4446715
OptimizeRx® (OTCQB:OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs). The company’s cloud-based solution supports patient adherence to medications by providing convenient access to financial assistance, prior authorization, education, and critical clinical information. The company’s network is comprised of more than 370 independent EHR platforms, providing more than half a million healthcare providers access to these benefits within their e-prescribing workflow and at the point of care. The largest of its kind, the OptimizeRx EHR network helps improve patient care and outcomes by providing a direct channel for pharma companies to communicate with healthcare providers. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2017 AND DECEMBER 31, 2016
|Cash and cash equivalents||$||5,013,128||$||7,034,647|
|Total Current Assets||7,964,686||10,175,863|
|Property and equipment, net||180,459||173,649|
|Patent rights, net||721,476||772,394|
|Web development and other intangible costs, net||942,972||351,804|
|Total Other Assets||1,669,497||1,129,247|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accounts payable – trade||$||720,758||$||369,214|
|Revenue share payable||1,877,991||2,622,517|
|Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued and outstanding||-||-|
|Common stock, $.001 par value, 500,000,000 shares authorized, 29,275,117 and 29,718,867 shares issued and outstanding, respectively||29,275||29,719|
|Total Stockholders’ Equity||6,052,242||7,812,179|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||9,814,642||$||11,478,759|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016
|For the Three Months Ended||For the Nine Months Ended|
|September 30||September 30|
|REVENUE SHARE EXPENSE||1,703,676||723,396||4,690,943||2,539,021|
|LOSS FROM OPERATIONS||(629,658||)||(249,218||)||(1,890,661||)||(1,213,582||)|
|OTHER INCOME (EXPENSE)|
|TOTAL OTHER INCOME (EXPENSE)||6,872||6,634||23,691||27,129|
|LOSS BEFORE PROVISION FOR INCOME TAXES||(622,786||)||(242,584||)||(1,866,970||)||(1,186,453||)|
|PROVISION FOR INCOME TAXES||-||-||-||-|
|WEIGHTED AVERGE NUMBER OF SHARES OUTSTANDING|
|BASIC AND DILUTED||29,256,367||29,433,846||29,517,975||29,374,319|
|NET LOSS PER SHARE|
|BASIC AND DILUTED||$||(0.02||)||$||(0.01||)||$||(0.06||)||$||(0.04||)|
Source: OptimizeRx Corporation